.png)
Runatek is an innovative Medtech startup
Revolutionizing Outpatient Pain Management
Innovative Technology
Feedback control of medication delivery ensures proper concentration of medication for each patient, eliminating misuse and providing better recovery care.
Market Need
Intended for acute post-surgical pain management following outpatient total joint replacement, giving mobility to patients and alleviating post-operative pain.
Growing Target Market
Total serviceable market of over 800,000 outpatient total joint replacement procedures within five years.
Qualified Team
Experts in the fields of engineering, medicine, and finance, and have been able to design and develop its product with the assistance of major universities.
FOR INVESTORS
We are seeking professional experienced venture capital investors to join our team and help take us to the next level. We are conducting our seed round of $700k on a convertible note to raise capital to get our technology through the FDA approvals process and onto the market. For more information on the Seed round, please contact CFO Stephen Swain at sswain@runatek.com
THE FUTURE OF PAIN MANAGEMENT
Runatek has designed the first outpatient, wearable, smart drug delivery device with feedback control, the Sotiras. We have patents pending on our technology. Its initial market is acute care pain management after total joint replacement surgery, with the cost covered by the insurance provider. We are a less risky, more effective alternative to opioid tablets, with much better control over these restricted and potentially addictive drugs.